Amgen Research (munich) Gmbh

Micromet Ag

Amgen Research Gmbh

Meera Berry

Peter Kufer

Tobias Raum

Birgit Kohleisen

Patrick A Baeuerle

Andreas Wolf

Sonja Offner

Christian Itin

Klaus Brischwein

Roman Kischel

Susanne Mangold

Patrick Bäuerle

Steven Zeman

Ulla Lenkkeri-Schütz

Eva Krinner

Ulla Lenkkeri-Schutz

Patrick Bauerle

The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.

Pharmaceutical composition comprising a bispecific antibody for EpCAM

The present invention provides a method for the preparation of a human binding molecule, fragment or derivative thereof which specifically binds to the human CD3 complex. Furthermore, the invention provides a human binding molecules specifically binding to the human CD3 complex and means comprising said human binding molecules.

Human-anti-human cd3 binding molecules

The present invention discloses bispecific antibodies comprising two antibody variable domains on a single polypeptide chain, wherein a first portion of the bispecific antibody is capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen on the human immune effector cell, the first portion consisting of one antibody variable domain, and a second portion of the bispecific antibody specifically binding to a target antigen other than the effector antigen, the target antigen on a target cell other than the human immune effector cell, the second portion comprising one antibody variable domain.

Bispecific antibodies

Growing community of inventors

Ulm, Germany

Meera Berry